title: Psoriasis aggravation due to lapatinib.
abstract: Our patient was a 35-year-old woman, who had undergone right radically modified mastectomy and axillary-lymph-nodes dissection in June 2004. The stage of the patient was T2N0M0. She was treated with six cycles of FAC (5-fluorouracil, doxorubicin, cyclofosfamid), tamoxifen after chemotherapy. In June 2008, right axillary lymphadenopathy progressed and was treated with docetaxel and capecitabine after a hand-foot reaction was observed in the patient as an adverse reaction to capacitabine; the treatment was continued with only trastuzmab between February 2009 and April 2010. The addition of vinoralbine was needed due to the newly developed right paratracheal lymphadenopthy in April 2010. After six cycles of chemotherapy we achieved stable disease; she received only trastuzumab; later on, in control thorax CT, multiple metastatic models were observed in April 2011 and thus lapatinip plus capecitabine treatment was started. After one cycle of chemotherapy her psoriatic lesions were aggravated and we had to stop the treatment.
authors: SB Okmeydani Training Hospital, Istanbul, Turkey. meltemtselam@yahoo.com
authors: Meltem
authors: M
authors: Selam
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery; D018450:Disease Progression; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D000077341:Lapatinib; D011565:Psoriasis / Q000139:chemically induced*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib; C512478:EGFR protein, human; D066246:ErbB Receptors
references: Ann Oncol. 2008 Jun;19(6):1068-74
references: 18283035
references: Am J Clin Dermatol. 2000 May-Jun;1(3):159-65
references: 11702297
references: Ann Oncol. 2009 Jun;20(6):1026-31
references: 19179558
references: Biologics. 2009;3:289-301
references: 19707416
references: J Eur Acad Dermatol Venereol. 2001 Jan;15(1):16-7
references: 11451313
references: Cancer. 2010 Aug 15;116(16):3916-23
references: 20564072
references: Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):121-8
references: 15180464
references: J Clin Oncol. 2008 Jun 20;26(18):2999-3005
references: 18458039
references: Breast Cancer Res Treat. 2008 Dec;112(3):533-43
references: 18188694
references: N Engl J Med. 2006 Dec 28;355(26):2733-43
references: 17192538
references: J Drugs Dermatol. 2006 May;5(5):426-32
references: 16703778